CD274 and liver cancer: In the advanced liver cancer field, there are currently FDA-approved PD-1/PD-L1 inhibitors, including nivolumab (PD-1 inhibitor), pembrolizumab (PD-1 inhibitor), camrelizumab (PD-1 inhibitor), tislelizumab (PD-1 inhibitor), durvalumab (PD-L1 inhibitor), atezolizumab (PD-L1 inhibitor) and durvalumab (PD-L1 inhibitor).